Article
Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
International journal of hematology - 1 Jun 2013
Bhagwat Neha, Levine Ross L, Koppikar Priya
Abstract excerpt
The discovery of activating mutations in JAK2 and MPL in a majority of patients with myeloproliferative neoplasms (MPN) has led to the rapid clinical development of several JAK kinase inhibitors. Of these, the JAK1/2 inhibitor, ruxolitinib (INCB018424, Incyte Corporation) was recently approved for the treatment of patients with myelofibrosis (MF). JAK inhibitors have effectively reduced splenomegaly and high...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.